StarMab announces that US FDA has approved its Investigational New Drug (IND) application for SM2275, a novel dual-target nanobody-based anti-tumor therapy. BEIJING, CHINA, April 7, 2025 /⁨EINPresswire.com⁩/ -- Beijing StarMab BioMed Technology , Ltd. (“ …